Skip to main content
Erschienen in: Supportive Care in Cancer 3/2014

01.03.2014 | Original Article

Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting

verfasst von: Eran Ben-Arye, Dikla Kruger, Noah Samuels, Lital Keinan-Boker, Tamar Shalom, Elad Schiff

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Patients with cancer are frequently turning to complementary medicine (CM), often with the goal of improving quality of life outcomes. The purpose of the present study was to assess the adherence of patients referred by oncology practitioners to a CM consultation and treatment program.

Patients and methods

A prospective registry protocol-based, preference study was conducted at a conventional oncology department. Patients undergoing chemotherapy were referred by participating oncology practitioners to a CM-trained integrative physician (IP) for consultation. Adherence to the integrative care (AIC) program was defined as attendance by patients at ≥4 CM treatment sessions, with an interval of no more than 30 days between each session.

Results

A total of 282 patients were referred by the study health-care professionals (HCPs), of whom 243 (85.8 %) were eventually seen by the study IP. Of these, 160 were found to be adherent to the treatment plan (AIC group), and 83 were nonadherent (non-AIC group). No significant differences were found between the two groups with respect to demographic characteristics, medical history, site of malignancy and/or recurrence, chemotherapy regimen, or severity of symptoms at baseline. The AIC group reported significantly greater rates of CM use for noncancer-related indications than the non-AIC group (EXP(B) = 2.174, 95 % confidence interval (C.I.) = 1.1–4.295, p = 0.025). Patients in the non-AIC group were referred more frequently by their HCP for gastrointestinal concerns than those in the AIC group (p = 0.022).

Conclusions

Previous use of CM for noncancer-related outcomes was found to be predictive of patient adherence to a CM treatment regimen provided within conventional oncology service.
Literatur
1.
Zurück zum Zitat Navo M, Phan J, Vaughan C, Palmer J, Michaud L, Jones K, Bodurka D, Basen-Engquist K, Hortobagyi G, Kavanagh J, Smith J (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22(4):671–677PubMedCrossRef Navo M, Phan J, Vaughan C, Palmer J, Michaud L, Jones K, Bodurka D, Basen-Engquist K, Hortobagyi G, Kavanagh J, Smith J (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22(4):671–677PubMedCrossRef
2.
Zurück zum Zitat Gansler T, Kaw C, Crammer C, Smith T (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113(5):1048–1057PubMedCrossRef Gansler T, Kaw C, Crammer C, Smith T (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113(5):1048–1057PubMedCrossRef
3.
Zurück zum Zitat Frenkel M, Cohen L, Peterson N et al (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283PubMedCrossRef Frenkel M, Cohen L, Peterson N et al (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283PubMedCrossRef
4.
Zurück zum Zitat Deng G (2008) Integrative cancer care in a US academic cancer centre: The Memorial Sloan-Kettering Experience. Curr Oncol 15(Suppl 2):s108, es68-71PubMedCentralPubMed Deng G (2008) Integrative cancer care in a US academic cancer centre: The Memorial Sloan-Kettering Experience. Curr Oncol 15(Suppl 2):s108, es68-71PubMedCentralPubMed
6.
Zurück zum Zitat Deng G, Frenkel M, Cohen L et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7(3):85–120PubMed Deng G, Frenkel M, Cohen L et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7(3):85–120PubMed
7.
Zurück zum Zitat Gaboury I, April KT, Verhoef M (2012) A qualitative study on the term CAM: is there a need to reinvent the wheel? BMC Complement Altern Med 12:131PubMedCentralPubMedCrossRef Gaboury I, April KT, Verhoef M (2012) A qualitative study on the term CAM: is there a need to reinvent the wheel? BMC Complement Altern Med 12:131PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Caspi O, Sechrest L, Pitluk HC, Marshall CL, Bell IR, Nichter M (2003) On the definition of complementary, alternative, and integrative medicine: societal mega-stereotypes vs. the patients’ perspectives. Altern Ther Health Med 9(6):58–62PubMed Caspi O, Sechrest L, Pitluk HC, Marshall CL, Bell IR, Nichter M (2003) On the definition of complementary, alternative, and integrative medicine: societal mega-stereotypes vs. the patients’ perspectives. Altern Ther Health Med 9(6):58–62PubMed
9.
Zurück zum Zitat Ben-Arye E, Schiff E, Golan O (2008) Ethical issues in integrative oncology. Hematol/Oncol Clin N Am 22(4):737–753CrossRef Ben-Arye E, Schiff E, Golan O (2008) Ethical issues in integrative oncology. Hematol/Oncol Clin N Am 22(4):737–753CrossRef
10.
Zurück zum Zitat Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511PubMedCrossRef Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511PubMedCrossRef
11.
Zurück zum Zitat Ben-Arye E, Schiff E, Shapira C, Frenkel M, Shalom T, Steiner M (2012) Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns 89(3):423–429PubMedCrossRef Ben-Arye E, Schiff E, Shapira C, Frenkel M, Shalom T, Steiner M (2012) Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns 89(3):423–429PubMedCrossRef
12.
Zurück zum Zitat Ben-Arye E, Schiff E, Steiner M, Keshet Y, Lavie O (2012) Attitudes of patients with gynecological and breast cancer toward integration of complementary medicine in cancer care. Int J Gynecol Cancer 22(1):146–153PubMedCrossRef Ben-Arye E, Schiff E, Steiner M, Keshet Y, Lavie O (2012) Attitudes of patients with gynecological and breast cancer toward integration of complementary medicine in cancer care. Int J Gynecol Cancer 22(1):146–153PubMedCrossRef
13.
Zurück zum Zitat Oldenmenger W, de Raaf P, de Klerk C, van der Rijt C (2012) Cut points on 0–10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manag 45(6):1083–1093. doi:10.1016/j.jpainsymman.2012.06.007 CrossRef Oldenmenger W, de Raaf P, de Klerk C, van der Rijt C (2012) Cut points on 0–10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manag 45(6):1083–1093. doi:10.​1016/​j.​jpainsymman.​2012.​06.​007 CrossRef
14.
Zurück zum Zitat Paterson C, Thomas K, Manasse A, Cooke H, Peace G (2007) Measure Yourself Concerns and Wellbeing (MYCaW): an individualized questionnaire for evaluating outcome in cancer support care that includes complementary therapies. Complement Ther Med 15(1):38–45PubMedCrossRef Paterson C, Thomas K, Manasse A, Cooke H, Peace G (2007) Measure Yourself Concerns and Wellbeing (MYCaW): an individualized questionnaire for evaluating outcome in cancer support care that includes complementary therapies. Complement Ther Med 15(1):38–45PubMedCrossRef
15.
Zurück zum Zitat Lazenby M, Khatib J, Al-Khair F, Neamat M (2013) Psychometric properties of the Functional Assessment of Chronic Illness Therapy–Spiritual Well-being (FACIT-Sp) in an Arabic-speaking, predominantly Muslim population. Psycho-oncology 22(1):220–227PubMedCrossRef Lazenby M, Khatib J, Al-Khair F, Neamat M (2013) Psychometric properties of the Functional Assessment of Chronic Illness Therapy–Spiritual Well-being (FACIT-Sp) in an Arabic-speaking, predominantly Muslim population. Psycho-oncology 22(1):220–227PubMedCrossRef
16.
Zurück zum Zitat Liang S, Yates P, Edwards H, Tsay S (2008) Factors influencing opioid-taking self-efficacy and analgesic adherence in Taiwanese outpatients with cancer. Psycho-oncology 17(11):1100–1107PubMedCrossRef Liang S, Yates P, Edwards H, Tsay S (2008) Factors influencing opioid-taking self-efficacy and analgesic adherence in Taiwanese outpatients with cancer. Psycho-oncology 17(11):1100–1107PubMedCrossRef
17.
Zurück zum Zitat Moynihan C, Norman A, Barbachano Y, Burchell L, Huddart R, Dearnaley D, Horwich A (2009) Prospective study of factors predicting adherence to medical advice in men with testicular cancer. J Clin Oncol 27(13):2144–2150PubMedCrossRef Moynihan C, Norman A, Barbachano Y, Burchell L, Huddart R, Dearnaley D, Horwich A (2009) Prospective study of factors predicting adherence to medical advice in men with testicular cancer. J Clin Oncol 27(13):2144–2150PubMedCrossRef
18.
Zurück zum Zitat Kahn K, Schneider E, Malin J, Adams J, Epstein A (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRef Kahn K, Schneider E, Malin J, Adams J, Epstein A (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439PubMedCrossRef
19.
Zurück zum Zitat Neymark N, Crott R (2005) Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer 13(10):812–818PubMedCrossRef Neymark N, Crott R (2005) Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer 13(10):812–818PubMedCrossRef
20.
Zurück zum Zitat Frenkel M, Cohen L (2008) Incorporating complementary and integrative medicine in a comprehensive cancer center. Hematol/Oncol Clin N Am 22(4):727–736CrossRef Frenkel M, Cohen L (2008) Incorporating complementary and integrative medicine in a comprehensive cancer center. Hematol/Oncol Clin N Am 22(4):727–736CrossRef
Metadaten
Titel
Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting
verfasst von
Eran Ben-Arye
Dikla Kruger
Noah Samuels
Lital Keinan-Boker
Tamar Shalom
Elad Schiff
Publikationsdatum
01.03.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2016-z

Weitere Artikel der Ausgabe 3/2014

Supportive Care in Cancer 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.